As a new year begins, plans are underway for the 8 th Annual Rare Disease Genomics Symposium to be held on February 26 th and 27 th. The two-day event will be virtual this year to limit the spread of ...

CHICAGO -- Selumetinib (Koselugo) significantly improved response rates in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas, the phase III KOMET trial ...

This month, our discussion focuses on the clinical management of plexiform neurofibromas in the era of selumetinib, a MEK inhibitor medication that was approved by the FDA in 2020 for the treatment of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Gomekli is the first treatment of its kind to be ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mirdametinib is an investigational mitogen-activated ...

Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements. The ...

Findings from the ReNeu trial showed treatment with mirdametinib resulted in statistically significant objective response rates. The Food and Drug Administration (FDA) has accepted for Priority Review ...

A new preclinical model of pulmonary arterial hypertension (PAH) may lead to improved research and ultimately better therapies for this life-threatening problem, according to its developers. A new ...

We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit. Children with ...

The Business Research Company's Plexiform Neurofibroma Treatment Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research Company's Plexiform Neurofibroma ...